Figure 2From: Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugateThe tumor and serum (the representative HT29 tumor bearing mouse) was pretreated with excess fold of bevacizumab: tumor VEGF (a-b) and serum VEGF (c-d). Tumor VEGF in the pretreated group of mice is significantly (p = 0.002) suppressed (b) in the accumulation of bevacizumab-AlexaFluor 750 in comparing with untreated tumor Figure 2(a), while the serum VEGF is relatively higher (d) comparing to the untreated serum (c).Back to article page